Committed to the discovery, development and commercialization of oral direct-acting antiviral therapies.

HCV

Bemnifosbuvir + ruzasvir

The regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor and ruzasvir,
an NS5A inhibitor, is advancing to a global Phase 3 program for the treatment of
hepatitis C virus (HCV). As single agents, both bemnifosbuvir and ruzasvir have
demonstrated potent pan-genotypic antiviral activity against HCV.

ATEA PHARMACEUTICALS

Combining innovative discoveries with development expertise to advance antivirals with the potential to transform treatments for patients with serious viral diseases.

Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies.

Advancing Oral Antiviral Therapies with Multibillion Dollar Market Opportunities

Hepatitis C (HCV)

Innovative Therapies to Address Unmet Medical Needs

Hepatitis C (HCV)

Our science.

Leveraging our deep understanding of antiviral drug development, medicinal chemistry, biology, biochemistry and virology, we are discovering and developing novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Currently, we are focused on the development of orally-available direct-acting antiviral agents for the treatment of hepatitis C virus (HCV).

A network of hubs and spokes is suspended, representing the idea of a modular platform.

NEWS

Follow our progress.

Updates on the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV and

other Atea news.

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Enters into Agreement with Bradley L. Radoff and Michael Torok BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, Including up to 4 Million in US New

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today issued the following statement: The Atea Board